AUROPHARMA

💊 is back in action!

💊

is back in action as its subsidiary Lyfius Pharma has resumed Penicillin-G production at the Kakinada plant after getting approval from the Andhra Pradesh Pollution Control Board on June 29, 2025. 🏭 This move strengthens its antibiotics segment and signals positive momentum for future growth. 📌 Aurobindo continues to deliver in APIs, generics, and formulations across pain relief, antibiotics & osteoporosis care. 👀 Smart investors, stay tuned — this restart could mean stronger days ahead! 🚀